Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantation

Yaara Yerushalmi, Noga Shem-Tov, Ivetta Danylesko, Jonathan Canaani, Abraham Avigdor, Ronit Yerushalmi, Arnon Nagler, Avichai Shimoni, Yaara Yerushalmi, Noga Shem-Tov, Ivetta Danylesko, Jonathan Canaani, Abraham Avigdor, Ronit Yerushalmi, Arnon Nagler, Avichai Shimoni

Abstract

Second allogeneic hematopoietic stem-cell transplantation (HSCT2) is a therapeutic option for patients with acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) relapsing after a first transplant (HSCT1). However, patients allocated to HSCT2 may be a selected group with better prognosis and the added efficacy of HSCT2 is not well established. We retrospectively analyzed 407 consecutive patients with relapsed AML/MDS after HSCT1. Sixty-two patients had HSCT2 (15%) and 345 did not. The 2-year cumulative incidence rates of non-relapse mortality and relapse after HSCT2 were 26% (95% confidence interval [95% CI]: 17-39%) and 50% (95% CI: 39-65%), respectively. The 5-year overall survival rates were 25% (95% CI: 14-36%) and 7% (95% CI: 4-10%) in the HSCT2 and no-HSCT2 groups, respectively. Multivariate analysis identified female gender (hazard ratio [HR]=0.31, P=0.001), short remission duration after HSCT1 (HR=2.31, P=0.05), acute graft-versus-host disease after HSCT1 (HR=2.27, P=0.035), HSCT2 from a haplo-identical donor (HR=13.4, P=0.001) or matched unrelated donor (HR=4.53, P=0.007) and relapse after HSCT1 in earlier years (HR=2.46, P=0.02) as factors predicting overall survival after HSCT2. Multivariate analysis of all patients including HSCT2 as a timedependent variable identified relapse within 6 months after HSCT1 (HR=2.32, P<0.001), acute graft-versus-host disease before relapse (HR=1.47, P=0.005), myeloablative conditioning in HSCT1 (HR=0.67, P=0.011), female gender (HR=0.71, P=0.007), relapse in earlier years (HR=1.33, P=0.031) and not having HSCT2 (HR=1.66, P=0.010) as predictive of overall survival after relapse. In conclusion, HSCT2 is associated with longer survival compared to non-transplant treatments and may be the preferred approach in a subset of patients with relapsed AML/MDS after HSCT1.

Figures

Figure 1.
Figure 1.
Figure 1. Outcomes after second allogeneic hematopoietic stem cell transplantation. (A) Non-relapse mortality. (B) Relapse. (C) Overall survival. HSCT2: second hematopoietic stem cell transplantation.
Figure 2.
Figure 2.
Overall survival afer relapse. (A) Overall survival in 345 patients not given a second hematopoietic stem cell transplant (HSCT2) compared with overall survival after HSCT2 in 62 recipients (calculated from the day of the second transplant). (B) Landmark analysis at 60 days after relapse according to whether patients did or did not have a HSCT2.

References

    1. Gooley TA, Chien JW, Pergam SA, et al. . Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091-2101.
    1. Shimoni A, Labopin M, Finke J, et al. . Donor selection for a second allogeneic stem cell transplantation on AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT. Blood Cancer J. 2019;9(12):88.
    1. Bejanyan N, Weisdorf DJ, Logan BR, et al. . Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transplant. 2015;21(3):454-459.
    1. Bazarbachi A, Schmid C, Labopin M, et al. . Evaluation of trends and prognosis over time in patients with AML relapsing after allogeneic hematopoietic cell transplant reveals improved survival for young patients in recent years. Clin Cancer Res. 2020;26(24):6475-6482.
    1. Shem-Tov N, Saraceni F, Danylesko I, et al. . Isolated extramedullary relapse of acute leukemia after allogeneic stem cell transplantation: different kinetics and better prognosis than systemic relapse. Biol Blood Marrow Transplant. 2017;23(7):1087-1094.
    1. Schmid C, Labopin M, Nagler A, et al. . Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood. 2012;119(6):1599-1606.
    1. Zuanelli Brambilla C, Lobaugh SM, Ruiz JD, et al. . Relapse after allogeneic stem cell transplantation of acute myelogenous leukemia and myelodysplastic syndrome and the importance of second cellular therapy. Transplant Cell Ther. 2021;27(9):771.
    1. Eapen M, Giralt SA, Horowitz MM, et al. . Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant. 2004;34(8):721-727.
    1. Shaw BE, Mufti GJ, Mackinnon S, et al. . Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of hematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant. 2008;42(12):783-789.
    1. Orti G, Sanz J, Bermudez A, et al. . Outcome of second allogeneic hematopoietic cell transplantation after relapse of myeloid malignancies following allogeneic hematopoietic cell transplantation: a retrospective cohort on behalf of the Grupo Español de Trasplante Hematopoyetico. Biol Blood Marrow Transplant. 2016;22(3):584-588.
    1. Christopeit M, Kuss O, Finke J, et al. . Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. J Clin Oncol. 2013;31(26):3259-3271.
    1. Yaniv I, Krauss AC, Beohou E, et al. . Second hematopoietic stem cell transplantation for post-transplantation relapsed acute leukemia in children: a retrospective EBMT-PDWP study. Biol Blood Marrow Transplant. 2018;24(8):1629-1642.
    1. Ruutu T, de Wreede LC, van Biezen A, et al. . Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. Bone Marrow Transplant. 2015;50(12):1542-1550.
    1. Michallet M, Tanguy ML, Socié G, et al. . Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Société Française de Greffe de Moelle (SFGM). Br J Haematol. 2000;108(2):400-407.
    1. Kharfan-Dabaja MA, Labopin M, Polge E, et al. . Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse. JAMA Oncol. 2018;4(9):1245-1253.
    1. Vrhovac R, Labopin M, Ciceri F, et al. . Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes. Bone Marrow Transplant. 2016;51(2):186-193.
    1. Kedmi M, Resnick IB, Dray L, et al. . A retrospective review of the outcome after second or subsequent allogeneic transplantation. Biol Blood Marrow Transplant. 2009;15(4):483-489.
    1. Bacigalupo A, Ballen K, Rizzo D, et al. . Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628-1633.
    1. Spyridonidis A, Labopin M, Savani BN, et al. . Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplant. 2020;55(6):1114-1125.
    1. Przepiorka D, Weisdorf D, Martin P, et al. . 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825-828.
    1. Jagasia MH, Greinix HT, Arora M, et al. . National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389-401.
    1. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
    1. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706.
    1. Döhner H, Estey E, Grimwade D, et al. . Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447.
    1. Thanarajasingam G, Kim HT, Cutler C, et al. . Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(12):1713-1718.
    1. Abbi KK, Zhu J, Ehmann WC, et al. . G-CSF mobilized vs conventional donor lymphocytes for therapy of relapse or incomplete engraftment after allogeneic hematopoietic transplantation. Bone Marrow Transplant. 2013;48(3):357-362.
    1. Baron F, Labopin M, Niederwieser D, et al. . Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Leukemia. 2012;26(12):2462-2468.
    1. Kharfan-Dabaja MA, Labopin M, Bazarbachi A, et al. . Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. Bone Marrow Transplant. 2021;56(9):2194-2202.
    1. Vago L, Perna SK, Zanussi M, et al. . Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med. 2009;361(5):478-488.
    1. Shimoni A, Labopin M, Savani B, et al. . Intravenous busulfan compared with treosulfan-based conditioning for allogeneic stem cell transplantation in acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2018;24(4):751-757.
    1. Shimoni A. Relapse of acute leukemia after a second allogeneic stem-cell transplantation; is there any hope for cure? Bone Marrow Transplant. 2022;57(3):336-337.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit